Blog

Seattle, Washington Mar 16, 2023 (Issuewire.com) – Findings from the TrialNet Abatacept Prevention Study, published online March 15 by Diabetes Care, provide important new information about how abatacept impacts type 1 diabetes progression, which will inform future research.

The Abatacept Prevention Study opened in 2013 and enrolled 212 participants between the ages of 6 and 45 who were at increased risk for type 1 diabetes. All participants had two or more diabetes-related autoantibodies and normal glucose tolerance (Stage 1). Risk was identified by TrialNet screening, which detects the autoantibodies that signal the disease in its earliest stages, often years before symptoms appear.

The study found that while abatacept impacted immune response and preserved insulin production during the one-year treatment period, it did not meet the study goal of delaying progression to abnormal glucose tolerance (Stage 2) or clinical diagnosis (Stage 3). The group treated with abatacept maintained beta cell function better than the placebo group at 12 months. However, 12 months after treatment ended, beta cell function was the same for both groups. The early effect was not sustained.

“Every study gives us critical information that moves us one step closer to our ultimate goal: a future without type 1 diabetes,” said Bill Russell, MD, TrialNet Abatacept Study Chair at Vanderbilt University in Nashville, TN. “This study helped us learn more about how abatacept works and its impact on disease progression.”

In the treatment phase of the study, participants received 14 intravenous (IV) infusions over one year–three in the first month, then monthly for 11 months. Assigned randomly by computer, half of the participants got the study drug; the other half got a placebo infusion (looks the same as the study drug but is inactive). Neither researchers nor participants knew who was in which group until the end of the study. After the first year, participants visited a TrialNet site twice a year for monitoring until the study ended.

In an earlier TrialNet study for people newly diagnosed with type 1 diabetes (Stage 3), participants were treated with abatacept for two years. At the end of two years, those treated with abatacept had 59% better insulin production and a 9.6-month average delay in progression of insulin loss compared to those who received the placebo. That difference extended out to three years.

“Comparing findings from both studies provides important new information and direction for future research,” said Dr. Russell.

Studying abatacept in both Stage 1 and Stage 3 opens the door to additional research asking: Would continued treatment make a difference? Would starting abatacept in Stage 2 be more effective? Could combining abatacept with another therapy prolong its impact?

Abatacept (CTLA-4 lg) changes the way immune cells communicate. Marketed as Orencia(R), abatacept is currently approved by the FDA for use in children as young as 6 for two types of juvenile arthritis and is also being studied for treatment of other autoimmune diseases.

TrialNet is currently planning a new study to test abatacept in combination with rituximab, another drug that targets the immune system, in people newly diagnosed with type 1 diabetes. Expected to open for enrollment later this year, this study will be the first to test these two drugs consecutively (one after the other). Separate TrialNet studies showed each drug individually helped preserve insulin production in people newly diagnosed. By combining the two therapies, researchers expect more individuals to maintain insulin production during and possibly after treatment.

The first step for those interested in participating in TrialNet research is to get screened. TrialNet risk screening is free, quick and convenient. Those identified as being in the early stages of type 1 diabetes may be eligible for monitoring and clinical studies to try to change the course of the disease. To learn more, contact info@trialnet.org or visit www.trialnet.org.

About TrialNet

The largest clinical trial network ever assembled to change the course of type 1 diabetes, TrialNet (NCT00097292) is funded by the National Institutes of Health (NIH), primarily through the Special Statutory Funding Program for Type 1 Diabetes. TrialNet research was instrumental in the FDA’s recent approval of the first drug to delay type 1 diabetes in people at risk. TrialNet conducted the clinical study that discovered teplizumab could delay type 1 diabetes for 2+ years. In addition, TrialNet data collected from more than 225,000 relatives of people with type 1 diabetes over the past 20 years led to the development of the stages of type 1 diabetes, making it possible to identify who will develop type 1 diabetes and move prevention research forward. Learn more at www.trialnet.org.

New Delhi, Delhi Mar 16, 2023 (Issuewire.com) – Aruna Sundararajan IAS (Retd.), former Secretary (Telecom), Department of Telecommunications, Ministry of Communications, Government of India, has been conferred with the Lifetime Achievement Award by the BRICS Chamber of Commerce and Industry (CCI) for her stellar contribution to the Digital India initiatives and for laying the groundwork for the 5G technology in the country.

Sundararajan, a 1982 batch Indian Administrative Service (IAS) officer, had led several citizen-centric innovative and transformative projects while helming multiple government departments during her career spanning over three decades.

The Lifetime Achievement felicitation by BRICS CCI was in recognition of her role in creating the highly-acclaimed National Digital Communication Policy (NDCP) 2018 and formulating India’s 5G policy, the group said in a statement.

During her illustrious career, Sundararajan has launched several initiatives including NDCP 2018, India’s 5G policy, a 5G High-Level Forum, and the Akshaya project of the southern Indian state of Kerala.

Sundararajan, who had served as Secretary in the Steel, IT, and Communications Ministries, had also worked as the country head of the Global e-Schools Initiative of the United Nations. She has served as Chairperson of the Digital Communications Commission (DCC).

As the founding IT Secretary of Kerala, she conceptualised the Akshaya project, an ambitious e-literacy initiative that paved the way for Kerala to become India’s first e-literate state.

She has now joined the Broadband India Forum (BIF) as Chairperson to guide the forum in its mission to improve affordable broadband proliferation and usage access in India.

Recognised by the United Nations, BRICS CCI is a not-for-profit organisation that provides a platform for active trade and commerce between the BRICS and other nations. It has a BRICS Women Entrepreneurship Vertical, a dedicated wing that aims to provide investment opportunities to women entrepreneurs worldwide.

Toronto, Ontario Mar 16, 2023 (Issuewire.com) – NIBAV Home Lifts, a leading provider of home lift solutions, is currently participating in the National Home Show, one of Canada’s premier home design and home improvement shows. The show is taking place at the Enercare Centre from March 10th to 19th, 2023. NIBAV Home Lifts is showcasing its latest product, the Series III Home Elevator, which is designed to provide homeowners with a safe, stylish, and efficient means of accessing multiple floors in their homes.

The National Home Show is an annual event that brings together thousands of homeowners, designers, and industry professionals from across Canada. The show features a wide range of exhibitors, seminars, and demonstrations, providing attendees with valuable insights and inspiration for their home design and renovation projects.

NIBAV Home Elevators is proud to be participating in this year’s event and showcasing its Series III Elevator, a state-of-the-art home lift system that offers unparalleled safety, customization, and energy efficiency. The Series III Elevator is designed to fit seamlessly into any residential property, providing homeowners with a compact, quiet, and reliable means of accessing multiple floors in their homes.

“This is a wonderful opportunity for us to reach out to the masses and propagate the significance of this important innovation – home elevators. This show has been amassing huge crowds, especially architects, homeowners, and the like so this is quite exciting for us to be able to participate in this show and showcase our Series III elevator”, says Mr. Vishal Babu, Director of NIBAV Home Lifts.

We can showcase how our home Elevator solutions can enhance mobility, accessibility, and overall quality of life for homeowners”

At the National Home Show, visitors to the NIBAV Home Lifts booth can see the Series III Elevator in action and speak with the company’s experienced professionals about their home lift requirements. The NIBAV team is on hand to provide expert advice on lift installation, customization, and maintenance, as well as answer any questions visitors may have.

About Nibav:

NIBAV Lifts has established itself as a leader in the premier home Elevator industry, thanks to its unwavering commitment to quality and safety. With a strong global presence spanning 14 countries, NIBAV has earned a reputation for excellence that’s unparalleled in the industry. The company’s 31 fully-operational experience centers around the world are a testament to its dedication to delivering impeccable service to its customers.

NIBAV prides itself on providing customizable solutions that enhance the homeowner’s quality of life. With a focus on safety and accessibility, the company’s latest range of home lifts offers a range of features and benefits that cater to the unique needs and preferences of each customer.

As the only brand with a coveted TUV SUD certification for home lifts, NIBAV remains committed to upholding the highest standards of quality and reliability. The company’s global footprint continues to expand, and it is poised to become a major player in the home lifts industry in many more countries around the world.

For more information, Contact us at https://www.nibavlifts.ca/contact/

Contact Information:

Office Address: Nibav Lifts INC, Office No 227/228, Suite 200, 5700 Yonge Street, Toronto, ON, M2M 4K2.

Phone: +1 888-844-1966

Email: info@nibavlifts.ca

Website: https://www.nibavlifts.ca/